CDKN1A and cardiovascular disorder: The expression of lincRNA-p21 is dramatically downregulated in coronary artery disease patients and atherosclerotic plaques of ApoE−/− mice, which showed that lincRNA-p21 may act as a therapeutic target to treat cardiovascular disorders and atherosclerosis [18].